Background/aims: Several authors have reported the presence of H. pylori in the human biliary tract. The aim of this study was to investigate the influence of the presence of H. pylori on the epithelial cell proliferation activity in the biliary tract with hepatolithiasis.
Methodology: A histopathological examination and polymerase chain reaction were used to detect the presence of H. pylori from fourteen patients with hepatolithiasis. The cell proliferation activity in the biliary epithelia was determined using proliferating cell nuclear antigen staining.
Results: A histopathological examination and polymerase chain reaction analysis demonstrated H. pylori to be detected in 5 (37%) and 4 (29%) out of 14 patients, respectively. The proliferating cell nuclear antigen labeling index was significantly higher in the H. pylori-positive patients (28.3%) than in the H. pylori-negative individuals (4.9%).
Conclusions: H. pylori is present in the biliary tract of patients with hepatolithiasis, while H. pylori promotes the formation of stones in the biliary tract. The development of intrahepatic cholangiocarcinoma might therefore be linked to the presence of H. pylori because of the accelerated activity of cell kinetics in the epithelium of the biliary tract.
Download full-text PDF |
Source |
---|
Pharmaceuticals (Basel)
December 2024
Preclinical Department, Faculty of Medicine, "Lucian Blaga" University of Sibiu, 550169 Sibiu, Romania.
Background/objectives: Pasireotide (PAS) is a somatostatin receptor ligand (SRL) used to treat acromegaly, a chronic condition caused by excess growth hormone. While it offers significant benefits as a second-line treatment for uncontrolled acromegaly, its use raises major concerns due to hyperglycemic side effects and gastrointestinal issues, the latter being similar to those seen with first-generation SRLs. The aim of this study is to evaluate the real-world evidence on adverse drug reactions (ADRs) reported for PAS in the EudraVigilance database, in comparison to other established drug-based therapies for acromegaly.
View Article and Find Full Text PDFMedicina (Kaunas)
November 2024
HPB Unit, Department of Surgery, University Hospital of Ioannina, 455 00 Ioannina, Greece.
: Laparoscopic cholecystectomy (LC) is the most commonly performed operation in general surgery in the Western World. Gallbladder surgery, although most of the time simple, always offers the possibility of unpleasant surprises. Despite progress, the incidence of common bile duct injury is 0.
View Article and Find Full Text PDFBiology (Basel)
November 2024
Nuclear Medicine Department, Institut Régional du Cancer de Montpellier (ICM), University Montpellier, 34090 Montpellier, France.
The tumor microenvironment (TME) is a dynamic and complex medium that plays a central role in cancer progression, metastasis, and treatment resistance. Among the key elements of the TME, cancer-associated fibroblasts (CAFs) are particularly important for their ability to remodel the extracellular matrix, promote angiogenesis, and suppress anti-tumor immune responses. Fibroblast activation protein (FAP), predominantly expressed by CAFs, has emerged as a promising target in both cancer diagnostics and therapeutics.
View Article and Find Full Text PDFHPB (Oxford)
December 2024
Department of Surgery, Fondazione Poliambulanza, Brescia, Italy. Electronic address:
Background: Ampullary adenocarcinoma (AAC) typically presents at an early stage due to biliary obstruction and therefore might be specifically suitable for minimally invasive pancreatoduodenectomy (MIPD). However, studies assessing MIPD specifically for AAC, including the robotic and laparoscopic approach, are limited. The aim of this study is to compare short- and long-term oncological resection and perioperative outcomes of robotic (RPD), laparoscopic (LPD) and open pancreatoduodenectomy (OPD) performed specifically for AAC.
View Article and Find Full Text PDFBackground: The addition of durvalumab or pembrolizumab to gemcitabine and cisplatin (GP) has been approved to statistically improve survival outcomes in patients with advanced biliary tract cancer. However, since the survival time was only prolonged by about two months, doubts have been raised. In this analysis, we aimed to evaluate the efficacy of combining durvalumab or pembrolizumab with GP chemotherapy.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!